Matched targeted therapy for pediatric patients with relapsed, refractory or high-risk leukemias: A report from the LEAP consortium.

被引：1
|
作者：
Pikman, Yana
Tasian, Sarah K.
Sulis, Maria Luisa
Blonquist, Traci M.
Maloney, Kelly W.
McNeer, Jennifer Lynn
Pauly, Melinda Gordon
Shukla, Neerav Narendra
Tyner, Jeffrey
Cole, Peter D.
Burke, Michael James
Gossai, Nathan
Brown, Patrick A.
Gore, Lia
Hunger, Stephen
Cooper, Todd Michael
Silverman, Lewis B.
Harris, Marian H.
Loh, Mignon L.
Stegmaier, Kimberly
机构：
[1] DFCI, Boston, MA USA
[2] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[3] Columbia Univ, Med Ctr, New York, NY USA
[4] Harvard Med Sch, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA
[5] Childrens Hosp Colorado, Aurora, CO USA
[6] Univ Chicago, Chicago, IL 60637 USA
[7] Emory Univ, Childrens Healthcare Atlanta, Atlanta, GA 30322 USA
[8] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[9] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[10] Childrens Hosp Montefiore, Bronx, NY USA
[11] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA
[12] Univ Minnesota, Minneapolis, MN USA
[13] Johns Hopkins Sch Med, Baltimore, MD USA
[14] Univ Colorado Comprehens Canc Ctr, Aurora, CO USA
[15] Dana Farber Canc Inst, Boston, MA 02115 USA
[16] Boston Childrens Hosp, Boston, MA USA
[17] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.10518
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10518
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium
    Pikman, Yana
    Tasian, Sarah K.
    Sulis, Maria Luisa
    Cooper, Todd M.
    Pauly, Melinda
    Maloney, Kelly W.
    Burke, Michael J.
    Brown, Patrick
    Gossai, Nathan
    Cole, Peter
    McNeer, Jennifer
    Shukla, Neerav
    Winger, Beth Apsel
    Adhav, Asmani A.
    Blonquist, Traci M.
    Conway, Amy
    Place, Andrew E.
    Gore, Lia
    Hunger, Stephen P.
    Janeway, Katherine
    Silverman, Lewis B.
    Tyner, Jeffrey W.
    Harris, Marian H.
    Loh, Mignon L.
    Stegmaier, Kimberly
    BLOOD, 2018, 132
  • [2] Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium
    Pikman, Yana
    Tasian, Sarah K.
    Sulis, Maria Luisa
    Stevenson, Kristen
    Blonquist, Traci M.
    Winger, Beth Apsel
    Cooper, Todd M.
    Pauly, Melinda
    Maloney, Kelly W.
    Burke, Michael J.
    Brown, Patrick A.
    Gossai, Nathan
    McNeer, Jennifer L.
    Shukla, Neerav N.
    Cole, Peter D.
    Kahn, Justine M.
    Chen, Jing
    Barth, Matthew J.
    Magee, Jeffrey A.
    Gennarini, Lisa
    Adhav, Asmani A.
    Clinton, Catherine M.
    Ocasio-Martinez, Nicole
    Gotti, Giacomo
    Li, Yuting
    Lin, Shan
    Imamovic, Alma
    Tognon, Cristina E.
    Patel, Tasleema
    Faust, Haley L.
    Contreras, Cristina F.
    Cremer, Anjali
    Cortopassi, Wilian A.
    Ruiz, Diego Garrido
    Jacobson, Matthew P.
    Dharia, Neekesh, V
    Su, Angela
    Robichaud, Amanda L.
    Conway, Amy Saur
    Tarlock, Katherine
    Stieglitz, Elliot
    Place, Andrew E.
    Puissant, Alexandre
    Hunger, Stephen P.
    Kim, Annette S.
    Lindeman, Neal, I
    Gore, Lia
    Janeway, Katherine A.
    Silverman, Lewis B.
    Tyner, Jeffrey W.
    CANCER DISCOVERY, 2021, 11 (06) : 1424 - 1439
  • [3] Targeted Treatment and Immunotherapy in High-risk and Relapsed/Refractory Pediatric Acute Lymphoblastic Leukemia
    Graiqevci-Uka, Violeta
    Behluli, Emir
    Spahiu, Lidvana
    Liehr, Thomas
    Temaj, Gazmend
    CURRENT PEDIATRIC REVIEWS, 2023, 19 (02) : 150 - 156
  • [4] Targeted sequencing in 388 patients with high-risk or recurrent/refractory pediatric extracranial solid malignancies: An interim report from the GAIN Consortium/iCat2 Study
    Corson, Laura B.
    Church, Alanna J.
    Reidy, Deirdre
    Kao, Pei-Chi
    Kang, Wenjun
    Pinto, Navin
    Maese, Luke
    Laetsch, Theodore W.
    Kim, AeRang
    Vear, Susan I.
    Macy, Margaret E.
    Applebaum, Mark A.
    Lee, Lobin A.
    Duong Doan
    Pinches, R. Seth
    Choi, Seong
    Forrest, Suzanne J.
    Clinton, Catherine M.
    Crompton, Brian D.
    MacConaill, Laura E.
    Volchenboum, Samuel L.
    Lindeman, Neal I.
    DuBois, Steven G.
    London, Wendy B.
    Janeway, Katherine A.
    CANCER RESEARCH, 2020, 80 (14) : 57 - 57
  • [5] Phase I study of 131I-MIBG with dinutuximab for patients with relapsed or refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium.
    Cash, Thomas
    Marachelian, Araz
    DuBois, Steven G.
    Chi, Yueh-Yun
    Groshen, Susan G.
    Shamirian, Anasheh
    Stout, Alina C.
    Macy, Margaret E.
    Pinto, Navin R.
    Desai, Ami Vijay
    Sondel, Paul M.
    Asgharzadeh, Shahab
    Weiss, Brian D.
    Mosse, Yael P.
    Matthay, Katherine K.
    Park, Julie R.
    Goldsmith, Kelly C.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Phase II study of alisertib, irinotecan, and temozolomide in children with relapsed and refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.
    DuBois, Steven G.
    Marachelian, Araz
    Fox, Elizabeth
    Kudgus, Rachel A.
    Reid, Joel M.
    Groshen, Susan G.
    Malvar, Jemily
    Bagatell, Rochelle
    Wagner, Lars M.
    Maris, John M.
    Hawkins, Randall
    Courtier, Jesse
    Lai, Hollie
    Goodarzian, Fariba
    Shimada, Hiroyuki
    Boucher, Najee
    Czarnecki, Scarlett
    Tsao-Wei, Denice D.
    Matthay, Katherine K.
    Mosse, Yael P.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome
    Gojo, Ivana
    Perl, Alexander
    Luger, Selina
    Baer, Maria R.
    Norsworthy, Kelly J.
    Bauer, Kenneth S.
    Tidwell, Michael
    Fleckinger, Stephanie
    Carroll, Martin
    Sausville, Edward A.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) : 1217 - 1227
  • [8] Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome
    Ivana Gojo
    Alexander Perl
    Selina Luger
    Maria R. Baer
    Kelly J. Norsworthy
    Kenneth S. Bauer
    Michael Tidwell
    Stephanie Fleckinger
    Martin Carroll
    Edward A. Sausville
    Investigational New Drugs, 2013, 31 : 1217 - 1227
  • [9] Disease control in patients treated with naxitamab for refractory/relapsed high-risk neuroblastoma
    Mora, Jaume
    Chan, Godfrey C.
    Morgenstern, Daniel A.
    Amoroso, Loredana
    Nysom, Karsten
    Faber, Joerg
    Wingerter, Arthur
    Bear, Melissa
    Rubio-San-Simon, Alba
    Tornoe, Karen
    Koep, Sharif
    During, Maria
    Kushner, Brian H.
    CANCER RESEARCH, 2024, 84 (17)
  • [10] Cellular Therapy in High-Risk Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter Syndrome
    Barbanti, Maria Chiara
    Appleby, Niamh
    Kesavan, Murali
    Eyre, Toby Andrew
    FRONTIERS IN ONCOLOGY, 2022, 12
12345